MX2022007371A - Tratamiento del hipoparatiroidismo. - Google Patents

Tratamiento del hipoparatiroidismo.

Info

Publication number
MX2022007371A
MX2022007371A MX2022007371A MX2022007371A MX2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A MX 2022007371 A MX2022007371 A MX 2022007371A
Authority
MX
Mexico
Prior art keywords
treatment
hypoparathyroidism
pth compound
patient
titrating
Prior art date
Application number
MX2022007371A
Other languages
English (en)
Inventor
Kennett Sprogøe
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of MX2022007371A publication Critical patent/MX2022007371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con un compuesto de PTH para usarse en el tratamiento de hipoparatiroidismo, en donde el tratamiento comprende administraciones diarias únicas del compuesto de PTH a un paciente y ajuste de la dosis del paciente fuera de la norma de cuidado dentro de las cuatro semanas a partir del momento en que se administró la primera dosis del compuesto de PTH.
MX2022007371A 2020-01-13 2021-01-12 Tratamiento del hipoparatiroidismo. MX2022007371A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20151350 2020-01-13
EP20192565 2020-08-25
EP20216065 2020-12-21
PCT/EP2021/050460 WO2021144249A1 (en) 2020-01-13 2021-01-12 Hypoparathyroidism treatment

Publications (1)

Publication Number Publication Date
MX2022007371A true MX2022007371A (es) 2022-07-12

Family

ID=74187267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007371A MX2022007371A (es) 2020-01-13 2021-01-12 Tratamiento del hipoparatiroidismo.

Country Status (11)

Country Link
US (1) US20230042670A1 (es)
EP (1) EP4090357A1 (es)
JP (1) JP2023510790A (es)
KR (1) KR20220128390A (es)
CN (1) CN115003320A (es)
AU (1) AU2021208398A1 (es)
BR (1) BR112022010419A2 (es)
CA (1) CA3161101A1 (es)
IL (1) IL294357A (es)
MX (1) MX2022007371A (es)
WO (1) WO2021144249A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009938A (es) 2016-03-01 2019-03-14 Ascendis Pharma Bone Diseases As Profarmacos de hormona paratiroidea (pth).
BR112019005793A2 (pt) 2016-09-29 2019-06-18 Ascendis Pharma Bone Diseases As compostos de pth com baixas proporções de pico-para-vale
SI3518960T1 (sl) 2016-09-29 2023-11-30 Ascendis Pharma Bone Diseases A/S, Odmerni režim za PTH spojino z nadzorovanim sproščanjem
AU2022350937A1 (en) * 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2024094673A1 (en) * 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
US20070203058A1 (en) 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
AU2005232371B2 (en) 2004-03-23 2010-10-14 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US20090016985A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
PT2237799T (pt) 2008-02-01 2019-07-05 Ascendis Pharma As Pró-fármaco compreendendo um ligador autoclivável
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
WO2011143406A2 (en) * 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
EP3473261A1 (en) 2010-05-21 2019-04-24 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
US8989456B2 (en) 2010-06-30 2015-03-24 Nec Solution Innovators, Ltd. Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US9561287B2 (en) 2011-08-12 2017-02-07 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
US20200354428A9 (en) * 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
BR112019005793A2 (pt) 2016-09-29 2019-06-18 Ascendis Pharma Bone Diseases As compostos de pth com baixas proporções de pico-para-vale
US20190224329A1 (en) * 2016-09-29 2019-07-25 Ascendis Pharma Bone Diseases A/S Incremental Dose Finding in Controlled-Release PTH Compounds
WO2019219896A1 (en) * 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
AU2020253560A1 (en) 2019-04-05 2021-11-25 Prolynx Llc Improved conjugation linkers

Also Published As

Publication number Publication date
KR20220128390A (ko) 2022-09-20
AU2021208398A1 (en) 2022-06-09
CN115003320A (zh) 2022-09-02
JP2023510790A (ja) 2023-03-15
IL294357A (en) 2022-08-01
BR112022010419A2 (pt) 2022-08-23
CA3161101A1 (en) 2021-07-22
WO2021144249A1 (en) 2021-07-22
EP4090357A1 (en) 2022-11-23
US20230042670A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
MX2022007371A (es) Tratamiento del hipoparatiroidismo.
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
NZ751972A (en) Treatment of prurigo nodularis
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
MX2021000714A (es) Preparacion medicinal para uso externo.
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
HUP0401634A2 (hu) LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты